Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers
Results
Phase 1/2
This trial looked at a drug called osimertinib for non small cell lung cancer. It was for people whose cancer:
had got worse despite having a type of drug called a
had grown into surrounding tissues or spread elsewhere in the body (advanced cancer)
This trial was open for people to join between 2013 and 2015. The researchers published the results in 2015 and 2018.
Recruitment start: 26 March 2013
Recruitment end: 30 January 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Fiona Blackhall
AstraZeneca
Experimental Cancer Medicine Centre (ECMC)
Last reviewed: 06 Jun 2019
CRUK internal database number: 11726
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
